IQVIA Holdings Inc., a leading global provider of clinical research services and healthcare intelligence, reported its second-quarter 2025 financial results with a revenue of $4,017 million, marking a 5.3% increase compared to the previous year. The company reported a GAAP net income of $266 million and an adjusted EBITDA of $910 million. The GAAP diluted earnings per share were reported at $1.54, while the adjusted diluted earnings per share stood at $2.81. The company's R&D Solutions booked $2.5 billion in the quarter, achieving a book-to-bill ratio of 1.12x, while the contracted backlog grew by 5.1% year-over-year to $32.1 billion. IQVIA's TAS segment experienced an 8.9% increase in revenue, totaling $1,628 million. IQVIA also reported a robust share repurchase activity, buying back $607 million of common stock in the second quarter and exceeding $1 billion in repurchases year-to-date. As of June 30, 2025, IQVIA's cash and cash equivalents stood at $2,039 million, with a net debt of $13,451 million. For the full year 2025, IQVIA has updated its guidance, projecting revenue between $16.1 billion and $16.3 billion, adjusted EBITDA between $3.75 billion and $3.825 billion, and adjusted diluted earnings per share ranging from $11.75 to $12.05.